Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

(2012) Maartje E. Visser et al.   EUROPEAN HEART JOURNAL

Antisense oligonucleotides for the treatment of dyslipidaemia

(2012) Maartje E. Visser et al.   EUROPEAN HEART JOURNAL

Long-Term Safety and Efficacy of Mipomersen in Patients with Familial Hypercholesterolemia Uncontrolled by Maximally Tolerated Lipid Lowering Therapy

(2012) P. Barton Duell et al.   Journal of Clinical Lipidology

Therapeutic potential of antisense oligonucleotides for the management of dyslipidemia

(2011) Rosanne M Crooke et al.   Clinical Lipidology

Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia

(2011) Fatima Akdim et al.   EUROPEAN HEART JOURNAL

Mipomersen, an antisense apolipoprotein B synthesis inhibitor

(2011) Damon A Bell et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy

(2010) Fatima Akdim et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

(2010) Frederick J Raal et al.   LANCET

Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia

(2009) Maartje E. Visser et al.   JOURNAL OF LIPID RESEARCH

Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100

(2008) Rosie Z. Yu et al.   BIOCHEMICAL PHARMACOLOGY

Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe

(2008) Rosie Z Yu et al.   CLINICAL PHARMACOKINETICS